All In Biotech

Drug Trial Radar · NCT04506905

Safety, Tolerability, and Pharmacokinetics Study of Elpipodect (MK-8189) in Participants With Schizophrenia and Healthy Participants (MK-8189-011)

A 2-Part Randomized Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Alternate MK-8189 Titration Regimens in Young Adult Participants With Schizophrenia and to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-8189 in Elderly Participants With Schizophrenia and Healthy Elderly

Last checked: Nov 20, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

63

Actual

Start

Aug 28, 2020

Primary completion

Mar 22, 2022

Study completion Mar 22, 2022

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Aug 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, 2-part clinical study of the safety, tolerability and pharmacokinetics of alternate elpipodect titration regimens. Part 1 assessed multiple dose once-daily titration regimens of elpipodect in young adult participants with schizophrenia. Part 2 assessed multiple once-daily doses of elpipodect in elderly participants with schizophrenia and healthy elderly participants.

Conditions

  • Schizophrenia

Interventions

  • ElpipodectDrug

    MK-8189, oral, 4 mg and/or 12 mg tablets for a total daily dose of 8, 16 or 24 mg QD according to randomization

  • PlaceboDrug

    Oral tablets of dose-matched placebo to MK-8189 according to randomization

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 & 2: Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 27 days
  2. Part 1 & 2: Number of Participants Discontinuing Study Treatment Due to an AETime frame: Up to approximately 27 days

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Woodland Research Northwest, LLC ( Site 0002)

    Rogers, Arkansas

  • Parexel ( Site 0004)

    Glendale, California

  • Collaborative NeuroScience Network ( Site 0008)

    Long Beach, California

  • Velocity Clinical Research, Hallandale Beach ( Site 0001)

    Hallandale, Florida

  • RCA at Fort Lauderdale Behavioral Health Center ( Site 0006)

    Oakland Park, Florida

  • Hassman Research Institute ( Site 0007)

    Berlin, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.